Average Co-Inventor Count = 10.85
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Nurix Therapeutics, Inc. (8 from 14 patents)
2. Flexus Biosciences, Inc. (8 from 8 patents)
3. Bristol-Myers Squibb Compnay (5 from 3,685 patents)
4. Gilead Sciences, Inc. (2 from 924 patents)
5. Rapt Therapeutics, Inc. (2 from 13 patents)
6. Flx Bio, Inc. (2 from 2 patents)
7. Celgene Corporation (1 from 550 patents)
25 patents:
1. 12421195 - Amorphous and crystalline forms of IDO inhibitors
2. 12404239 - Modulators of BCL6 as ligand directed degraders
3. 12234230 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
4. 12091426 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
5. 12049471 - Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
6. 11951133 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
7. 11932601 - Immunoregulatory agents
8. 11919863 - Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
9. 11739101 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
10. 11530229 - Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
11. 11464802 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
12. 11401267 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
13. 11242319 - Immunoregulatory agents
14. 11236049 - Amorphous and crystalline forms of IDO inhibitors
15. 11236048 - Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation